1. Introduction {#sec1}
===============

In the 1980s, gram-negative pathogens were successfully defeated using cephalosporins, carbapenems, and fluoroquinolones \[[@B1]\]. *K. pneumoniae* is one of the most widespread nosocomial pathogens causing urinary tract infections, bacteremia, and pneumonia in different parts of the world \[[@B2], [@B3]\]. Extensive use of antibiotics and thereby the development of various resistance mechanisms have led to the emergence of MDR (multidrug resistance) *K. pneumoniae* \[[@B4]\]. KPC- (*Klebsiella pneumoniae* carbapenemase-) producing *K. pneumoniae* strains are the most common carbapenamase-producing pathogens worldwide \[[@B5]\] that have also been reported in Iran in many studies \[[@B6]--[@B8]\]. Seventeen different types in the KPC family have been reported to date \[[@B9]\], among which one family is located on a conjugative plasmid that encodes resistance to gentamicin and tobramycin \[[@B10]\]. The *armA* gene, which is responsible for resistance to the majority of the aminoglycosides and is the most prevalent in Asia \[[@B11]\], was found to be located on the same plasmid of KPC-producing strains reported formerly from Italy \[[@B12]\], China \[[@B13]\], and Poland \[[@B14]\]. Coexistence of the resistance-inducing agents can result in the emerging of MDR *K. pneumoniae* strains. Epidemiological characterization of MDR *K. pneumoniae* can help to prevent the spread of resistant strains \[[@B15]\]. RAPD PCR (random amplification of polymorphic DNA PCR) is a simple, rapid, inexpensive, and widely used typing method which does not require advanced knowledge of DNA sequences of the target organism. RAPD typing has been successfully employed for epidemiological analysis of many bacteria \[[@B16]\] as well as clinical isolates of *K. pneumonia* \[[@B17]\].

This study aimed to detect the RAPD PCR fingerprint, antibiotic resistance patterns, and the presence of *armA* gene in clinical KPC-producing isolates and nonproducing isolates of *K. pneumoniae*.

2. Materials and Methods {#sec2}
========================

2.1. Bacterial Collection {#sec2.1}
-------------------------

From September 2015 to March 2016, clinical samples were collected from both inpatients and outpatients attending three hospitals in Tehran, Iran. The samples were transferred to the microbiology laboratory, and biochemical tests were performed to identify *K. pneumoniae*. The pure isolates were stored at −20°C in Trypticase soy broth containing 20% glycerol.

2.2. Susceptibility Testing and Phenotypic Detection of KPC {#sec2.2}
-----------------------------------------------------------

The antimicrobial susceptibility test was conducted using the Kirby--Bauer disk diffusion method on Mueller--Hinton agar (Merck, Germany). Also, for colistin-resistant isolates, MIC was determined through a broth microdilution method, according to the Clinical and Laboratory Standard Institute (CLSI) guidelines. The isolates were tested for susceptibility to the following 16 antimicrobial agents (MAST Group, Merseyside, UK): ofloxacin (OFX, 5 *μ*g), ciprofloxacin (CIP, 5 *μ*g), norfloxacin (NOR, 10 *μ*g), gentamicin (GM, 10 *μ*g), amikacin (AK, 30 *μ*g), streptomycin (HLS, 10 *μ*g), tobramycin (TOB, 10 *μ*g), kanamycin (K, 30 *μ*g), ticarcillin (TIC, 75 *μ*g), cefotaxim (CTX, 30 *μ*g), ceftazidime (CAZ, 30 *μ*g), azetreonam (ATM, 30 *μ*g), imipenem (IMI, 10 *μ*g), trimethoprim (TR, 5 *μ*g), chloramphenicol (C, 30 *μ*g), and colistin (CO, 10 *μ*g). *Escherichia coli* ATCC 25922 was used as a control strain. Also, detection of KPC enzyme was performed by the modified Hodge test \[[@B18]\].

2.3. Detection of armA Gene {#sec2.3}
---------------------------

Bacteria were cultured in Luria--Bertani (LB) broth medium and were incubated overnight at 37°C. DNA was extracted from *K. pneumoniae* isolates by using Genomic DNA Isolation Kit (Global Gene Network Bio, cat. no. k-3000, South Korea) according to the manufacturer\'s instruction. The presence of *armA* gene was evaluated using PCR technique with the *armA*-F: TCGGAACTTAAAGACGACGA and *armA*-R: CCATTCCCTTCTCCTTTCCA (designed in this study) sequences. The PCR product was analyzed by electrophoresis in a 1% (W/V) agarose gel in TBE buffer at 95 V for 45 min, stained with ethidium bromide, and observed under UV lighting using Gel Doc. Then, DNA sequencing was performed by Bioneer Company (Korea), blasted in NCBI, and analyzed by Finch TV software.

2.4. RAPD PCR {#sec2.4}
-------------

Molecular typing of *K. pneumoniae* isolates was performed using RAPD PCR analysis with the primer 640 (CGTGGGGCCT) (Faza Biotech, Tehran, Iran). Reaction mixtures (25 *µ*l) contained: 12.5 *µ*l (Exprime Taq Premix (2X) Mastermix (Global Gene Network Bio, cat. no. G-5000)), 7.5 *µ*l Distilled water, 200 pmol of primer, and 3 *µ*l DNA template. The program used was as follows: 5 min at 94°C followed by 36 cycles of 1 min at 94°C, 1 min at 36°C, and 2 min at 72°C followed by a final extension at 72°C for 9 min. PCR products were then electrophoresed on 1% agarose gels and visualized by ethidium bromide staining. To determine the similarity rate among the isolates, they were analyzed by the unweighted pair-group method with arithmetic mean (UPGMA) using GelClust software.

3. Results {#sec3}
==========

3.1. Bacterial Isolation {#sec3.1}
------------------------

Eighty-one *K. pneumoniae* were isolated from the patients (44 males and 37 females). Samples were isolated from different clinical specimens including urine, 49 (60.5%); blood cultures, 16 (19.7%); wounds, 5 (6.2%); sputum, 4 (5%); intra-abdominal, 3 (3.7%), and others 4 (5%). The hospital ward distribution was as follows: pediatric ward, 24 (29.6%); outpatient, 18 (22.2%); intensive care unit, 10 (12.3%); surgical unit, 6 (7.4%); infection unit, 2 (2.5%); and others, 21 (26%).

3.2. Determination of Antibiotic Resistance and KPC Enzyme Detection {#sec3.2}
--------------------------------------------------------------------

Antibiogram showed that the resistance rates of the isolates were as follows: ofloxacin 65%, ciprofloxacin 68.7%, norfloxacin 66.3%, gentamicin 66.3%, amikacin 51.8%, tobramycin 56.7%, kanamycin 79.5%, ticarcillin 82%, streptomycin 16.9%, cefotaxim 85.5%, ceftazidime 78.3%, azetreonam 79.5%, imipenem 45.8%, trimethoprim 74.7%, chloramphenicol 21.7%, and colistin 16.9%. One colistin-resistant isolate had a MIC of 8 *µ*g/ml, and the other all had MIC values of 4 *µ*g/ml. All the colistin-resistant isolates except one of them belonged to one hospital. Five colistin-resistant *K. pneumoniae* exhibited resistance to imipenem of which one was positive for KPC production. The antibiotic resistance pattern of the isolates is shown in [Table 1](#tab1){ref-type="table"}. The highest rate of the resistance belonged to the A9 pattern (64.2%) which found to be resistant to three flouroquinolons. Also, the lowest rate of resistance belonged to the A4 pattern (4.9%) which was resistant to ciprofloxacin, ofloxacin, norfloxacin, imipenem, amikacin, and colistin. MDR is generally determined as resistance to three or more classes of antibiotics \[[@B19]\]. In the present study, 66 out of 81 isolates were resistant to 3 or more classes of antibiotics; thereby, 81.5% of the isolates were found to be MDR. Also, the modified Hodge test showed that 6 isolates (7.4%) were positive for KPC production with 3 resistance patterns ([Table 2](#tab2){ref-type="table"}).

3.3. Molecular Detection {#sec3.3}
------------------------

The PCR showed that 54 isolates (66.7%) of the isolates had *armA* gene. Aminoglycoside resistance patterns in *armA* positive isolates were presented in [Table 3](#tab3){ref-type="table"}.

3.4. RAPD PCR {#sec3.4}
-------------

Genetic analysis of RAPD showed 30 distinct patterns from D1 to D30, as 5 distinct clusters ([Figure 1](#fig1){ref-type="fig"}). The information of isolates is shown in [Table 4](#tab4){ref-type="table"}. The isolates were considered as the same pattern if the level of similarity was ≥85%. The numbers of the isolates in each cluster (from cluster 1 to 5) were 18, 19, 14, 26, and 4, respectively. The highest redundancy belonged to pattern D1, D8, and D20. There was not any correlation between genetic patterns of the isolates and presence of *armA* gene or KPC production. The isolates which showed 100% similarity, belonging to different clusters, all found to have *armA* gene.

4. Discussion {#sec4}
=============

In the present study, 81 *K. pneumoniae* were isolated from clinical samples. Antibiotic resistance patterns and their relationships among different clonal isolates were investigated. Eleven antibiotic patterns were found (A1--A11), showing much diversity in the resistance patterns. In the study by Hassan et al. \[[@B16]\] and Ben-Hamouda et al. \[[@B17]\], different antibiotic resistance patterns were reported, too \[[@B20]\]. In the present study, 81.5% were MDR. The presence of multidrug resistance community acquired *K. pneumoniae* highlights the need for accurate planning to control and prevent of the dissemination of MDR strains. Most of the KPC-producing isolates harbored *armA* gene and were resistant to carbapenems, aminoglycosides, and fluoroquinolones. According to our previous study, Real Time PCR showed an increased expression level of OqxAB and AcrAB efflux pumps in fluoroquinolone-resistant isolates in comparison with the sensitive ones (data not shown). So, the role of efflux pump in creating fluoroquinolone-resistant strains could be identified in these isolates \[[@B21]\]. Also, the aminoglycoside resistance rates suggested 16S rRNA methylase activity. In the present study, approximately 70% of the aminoglycoside-resistant strains carried the *armA* gene as Zhou et al. reported \[[@B22]\]. Therefore, some of these *K. pneumoniae* isolates have three features of resistance: KPC, efflux pumps, and *armA* gene. So they can be resistant to fluoroquinolones, cephalosporins, carbapenems and a spectrum of aminoglycosides as well. These strains can turn out to an important challenge for community and hospital officials by disseminating among the patients in hospitals and making the treatment process more difficult. Coexistence of the active efflux pump, *armA* gene, and KPC enzymes in *K. pneumoniae* can help to resist against the combination therapy. This hypothesis is also recommended by Zacharczuk et al. \[[@B14]\] and Jiang et al. \[[@B13]\] who observed KPC production and *armA* gene in clinical isolates of *K. pneumoniae*.

Furthermore, about 17% of the isolates were resistant to colistin, among which all but one isolate had MIC 4 *µ*g/ml. Although colistin-resistant isolates were related to five different clusters, 42.9% of them belonged only to the fourth cluster from one hospital, indicating a genetically specific circulating cluster. Colistin is considered as effective treatment against MDR and carbapenem-resistant bacteria, such as *K. pneumoniae*, but resistance to this agent has begun to emerge. So, more studies to determine the best treatment for infections caused by resistant *K. pneumoniae* are needed. In the present study, genotyping analysis showed different genetic patterns among pathogenic *K. pneumoniae* isolates. Lim et al. \[[@B23]\], Ben-Hamouda et al. \[[@B17]\], Pai et al. \[[@B24]\], and Eftekhar and Nouri \[[@B25]\] performed separately the genotyping of clinical *K. pneumoniae* strains and showed that they were genetically diverse and heterogeneous. Therefore, this tool has got the ability to identify related and unrelated isolates. The correlation between the antibiotic resistance patterns and RAPD analysis demonstrated that different genetic patterns had different antibiotyping profiles. Also, KPC-producing *K. pneumoniae* were found to belong to different clusters, and the results of RAPD PCR implicated that there is no correlation between the genetic patterns and presence of *armA* gene or KPC-producing *K. pneumoniae*, as Ma et al. \[[@B26]\] reported that nonclonally spread of ESBL-producing *K. pneumoniae* strains with *armA* or *rmtB* mediates aminoglycoside resistance. It seems that because most resistance genes are carried by the mobile genetic elements, they can easily transmit among the bacteria.

Of importance, the low number of the isolates was one of our limitations. Collecting more clinical isolates, using more powerful discriminating typing methods such as PFGE and analysis of *armA* and *bla*~kpc~ genes\' expression level may improve the quality of our results in the following studies.

5. Conclusion {#sec5}
=============

Although fluoroquinolones seem to be a good choice for treating *Klebsiella* infections, several studies have shown increasing resistance of *K. pneumoniae* isolates to these agents. Aminoglycosides have been considered as an adequate therapeutic against both gram-negative and gram-positive pathogens and also combination therapy with *β*-lactams and aminoglycosides is well accepted for the treatment of the systemic infections caused by *K. pneumoniae*, so simultaneous detection of resistance creating agents to fluoroquinolones, *β*-lactams, and aminoglycosides in these strains is of clinical importance. Emphasis on the suitable use of antibiotics, effective infection control measures, and identification of antibiotic resistance mechanisms by molecular procedures are necessary to reduce the incidence of infections caused by antibiotic-resistant organisms.
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###### 

Antibiotic resistance patterns.

  Resistance pattern number   Number of isolates (%)   Antibiotics
  --------------------------- ------------------------ -----------------------------------------
  A1                          11 (13.6)                OFX, NOR, CIP, IMI, K, GM, AK, TOB, HLS
  A2                          19 (23.4)                OFX, NOR, CIP, IMI, GM, AK, TOB, K
  A3                          29 (35.8)                OFX, NOR, CIP, IMI, K, GM
  A4                          4 (4.9)                  CIP, OFX, NOR, IMI, AK, CO
  A5                          12 (14.8)                AK, GM, TOB, K, HLS
  A6                          25 (30.9)                CIP, OFX, NOR, IMI, AK
  A7                          33 (40.7)                CIP, OFX, NOR, IMI
  A8                          30 (37)                  CIP, OFX, NOR, AK
  A9                          52 (64.2)                CIP, OFX, NOR
  A10                         11 (13.6)                TR, TIC, C
  A11                         25 (30.9)                IMI, AK

OFX: ofloxacin; NOR: norfloxacin; CIP: ciprofloxacin; IMI: imipenem; GM: gentamicin; AK: amikacin; TOB: tobramycin; HLS: streptomycin; K: kanamycin; CO: colistin; TR: trimethoprim; TIC: ticarcillin; C: chloramphenicol.

###### 

Antibiotic resistance patterns and presence of *armA* gene.

  Isolate name   Resistance pattern                        *armA*
  -------------- ----------------------------------------- --------
  1              OFX, NOR, CIP, IMI, K, GM, AK, TOB, HLS   \+
  2              OFX, NOR, CIP, IMI, K, GM, AK, TOB        \+
  3              OFX, NOR, CIP, IMI, K, GM, AK, TOB        −
  4              OFX, NOR, CIP, IMI, K, GM                 −
  5              OFX, NOR, CIP, IMI, K, GM                 \+
  6              OFX, NOR, CIP, IMI, K, GM                 \+

OFX: ofloxacin; NOR: norfloxacin; CIP: ciprofloxacin; IMI: imipenem; K: kanamycin; GM: gentamicin; AK: amikacin; TOB: tobramycin; HLS: streptomycin.

###### 

Aminoglycoside resistance in *armA* positive isolates.

  Aminoglycosides   Resistant number (%)   *armA *+ number (%)
  ----------------- ---------------------- ---------------------
  Kanamycin         66 (79.5)              46 (69.7)
  Tobramycin        47 (56.7)              32 (68)
  Gentamicin        55 (66.3)              38 (69)
  Amikacin          43 (51.8)              32 (74.4)
  Streptomycin      14 (16.9)              12 (87.7)

###### 

Analysis of strains with their RAPD profiles.

  Isolate number   *armA*   KPC   Date             Origin           Department                    Hospital   RAPD pattern
  ---------------- -------- ----- ---------------- ---------------- ----------------------------- ---------- --------------
  1                −        −     February 2016    Urine            Gynecology and obstetrician   A          D1
  2                −        −     February 2016    Urine            Outpatient                    A          D1
  3                −        −     February 2016    Urine            Outpatient                    A          D1
  4                −        −     February 2016    Urine            Laparoscopy                   A          D1
  5                −        −     February 2016    Urine            Outpatient                    A          D1
  6                \+       −     September 2015   Wound            Others                        B          D1
  7                −        −     February 2016    Urine            Outpatient                    A          D1
  8                \+       −     October 2015     Blood            Pediatric                     C          D1
  9                −        −     February 2016    Urine            Rheumatology                  A          D1
  10               \+       −     March 2016       Urine            Nephrology                    A          D1
  11               −        −     February 2016    Urine            Others                        A          D2
  12               \+       −     December 2015    Blood            Hematology                    B          D3
  13               \+       −     January 2015     Wound            Surgery                       B          D3
  14               \+       −     January 2015     Urine            Pediatric                     C          D3
  15               −        \+    November 2015    Urine            Outpatient                    B          D4
  16               −        −     November 2015    Blood            Infectious                    B          D4
  17               \+       −     September 2015   Intraabdominal   Gastrointestinal              B          D5
  18               \+       \+    September 2015   Sputum           ICU                           B          D5
  19               −        −     February 2016    Urine            Cancer                        A          D6
  20               \+       −     October 2015     Sputum           Bone marrow transplantation   B          D7
  21               −        −     February 2016    Urine            Dermatology                   A          D8
  22               −        \+    February 2016    Urine            Cardiology                    A          D8
  23               \+       −     January 2015     Blood            Pediatric                     C          D8
  24               −        −     March 2016       Urine            Outpatient                    A          D8
  25               −        −     March 2016       Urine            Outpatient                    A          D8
  26               \+       −     January 2015     Blood            ICU                           B          D8
  27               −        −     January 2015     Sputum           ICU                           B          D8
  28               \+       −     December 2015    Urine            Outpatient                    B          D8
  29               \+       −     December 2015    Blood            Pediatric                     C          D8
  30               \+       −     December 2015    Blood            Pediatric                     C          D8
  31               \+       −     October 2015     Wound            Surgery                       B          D9
  32               \+       −     November 2015    Intraabdominal   Cancer                        B          D10
  33               −        −     October 2015     Others           NICU                          B          D10
  34               \+       −     November 2015    Blood            Pediatric                     C          D10
  35               \+       −     December 2015    Urine            Pediatric                     C          D11
  36               \+       −     September 2015   Sputum           ICU                           B          D12
  37               \+       −     October 2015     Wound            Surgery                       B          D12
  38               \+       −     March 2016       Urine            ICU                           A          D13
  39               \+       \+    March 2016       Urine            Others                        A          D13
  40               \+       −     January 2015     Blood            Pediatric                     C          D13
  41               \+       −     February 2016    Urine            Outpatient                    A          D14
  42               \+       −     January 2015     Others           Pediatric                     C          D14
  43               \+       −     January 2015     Urine            Pediatric                     C          D14
  44               \+       −     December 2015    Others           Outpatient                    B          D14
  45               \+       \+    December 2015    Urine            Pediatric                     C          D14
  46               \+       −     December 2015    Blood            Pediatric                     C          D14
  47               −        −     September 2015   Urine            Surgery                       B          D15
  48               −        −     February 2016    Urine            Outpatient                    A          D16
  49               \+       −     October 2015     Urine            Pediatric                     C          D17
  50               \+       −     November 2015    Urine            Endocrinology                 B          D18
  51               \+       −     November 2015    Blood            Pediatric                     C          D18
  52               −        −     March 2016       Urine            Cardiology                    A          D19
  53               \+       −     March 2016       Urine            Others                        A          D19
  54               −        −     March 2016       Urine            Pediatric                     A          D19
  55               −        −     March 2016       Urine            Outpatient                    A          D19
  56               −        −     January 2015     Urine            Pediatric                     C          D19
  57               −        −     February 2016    Urine            Pediatric                     A          D20
  58               −        −     February 2016    Urine            Surgery                       A          D20
  59               −        −     February 2016    Urine            ICU                           A          D20
  60               −        −     February 2016    Urine            Others                        A          D20
  61               \+       −     November 2015    Urine            Pediatric                     C          D20
  62               \+       −     November 2015    Urine            Outpatient                    B          D20
  63               \+       −     January 2015     Urine            Pediatric                     C          D20
  64               \+       −     November 2015    Blood            Outpatient                    B          D20
  65               \+       −     January 2015     Urine            Pediatric                     C          D20
  66               \+       −     January 2015     Others           Outpatient                    B          D20
  67               \+       −     September 2015   Wound            Others                        B          D21
  68               \+       −     November 2015    Blood            Hematology                    B          D22
  69               \+       −     November 2015    Blood            Pediatric                     C          D22
  70               \+       −     September 2015   Urine            NICU                          B          D22
  71               \+       −     September 2015   Urine            Pediatric                     C          D22
  72               \+       −     March 2016       Urine            Surgery                       A          D23
  73               \+       −     March 2016       Urine            Cardiology                    A          D24
  74               \+       −     December 2015    Blood            NICU                          B          D25
  75               −        −     February 2016    Urine            Pediatric                     A          D26
  76               \+       −     October 2015     Urine            Outpatient                    B          D27
  77               \+       −     December 2015    Urine            ICU                           B          D28
  78               −        −     February 2016    Urine            Outpatient                    A          D29
  79               −        −     February 2016    Urine            Outpatient                    A          D29
  80               \+       \+    January 2015     Intraabdominal   Infectious                    B          D29
  81               \+       −     November 2015    Blood            Pediatric                     C          D30
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